Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer

Pharmacogenomics

Volumn 12, Issue 3, 2011, Pages 433-442

  Lamas, Maria J ^a   Duran, Goretti ^a   Balboa, Emilia ^b   Bernardez, Beatriz ^a   Touris, Manuel ^a   Vidal, Yolanda ^a   Gallardo, Elena ^a   Lopez, Rafael ^a   Carracedo, Angel ^b,c   Barros, Francisco ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Fundacion Publica Galega de Medicina Xenomica   (Spain)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

biomarkers; colorectal cancer; GSTP1; mFolfox 6; oxaliplatin; pharmacogenetic; XPD Lys751Gln

Indexed keywords

ADENINE; ARGININE; BEVACIZUMAB; CETUXIMAB; CYTOSINE; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GUANINE; ISOLEUCINE; LYSINE; OXALIPLATIN; THYMINE; TUMOR MARKER; VALINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ANEMIA; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DNA EXTRACTION; DNA SEQUENCE; DRUG DOSE REDUCTION; ERCC1 GENE; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; GSTP1 GENE; HAPLOTYPE; HOMOZYGOTE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MTHFR GENE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENETICS; PREDICTION; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VARIABLE NUMBER OF TANDEM REPEAT; XPD GENE; XRCC1 GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; POLYMORPHISM, GENETIC;

EID: 79953250126     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.196     Document Type: Article

References (37)

1. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Biichler MW: Colorectal cancer. Lancet9454, 153-165 (2005). (Pubitemid 40091806)
2. Kweekel DM, Gelderblom H, Guchelaar HJ et al.: Pharmacology of oxallplatin and the use of pharmacogenomics to Individualize therapy. Cancer Treat. Rev. 31, 90-105 (2005). (Pubitemid 40542888)
3. Tournigand C, Andre T, Achille E et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. Clin. Oncol. 22, 229-237 (2004) (Pubitemid 41095086)
4. Colucci G, GebbiaV, Paoletti G et al: Phase III randomised trial of FOLFIRI versus 4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'ltalla Metidonale. Clin. Oncol. 23, 4866-4875 (2005). (Pubitemid 46223991)
5. De Gramont A, Figer A, Seymour M et al.: Leucovorin and fluorouracil with or without oxallplatin as first line treatment in advanced colorectal cancer. Clin. Oncol. 18, 2938-2947(2005).
6. Le Morvan V, Smith D, Laurand A et al.: Determination of ERCC2 Lys75lGln and GSTPl Ilel05Val gene polymorphism in colorectal cancer patients: relationships with treatment outcome. Pharmacogenomics 8, 1693-1703 (2007).
7. Stoehlmacher J, Park DJ, Zhang W et al.: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91, 344-354 (2004). (Pubitemid 39037082)
8. Ruzzo A, Graziano F, Loupakis F et al.: Pharmacogenomic profiling in patients with advanced colorectal cancer treated with first-line folfox-4 chemotherapy. Clin. Oncol. 25, 1247-1254 (2007). (Pubitemid 46640571)
9. Pare L, Marcuello E, Altes A et al.: Pharmacogenomic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br. J. Cancer 99, 1050-1055 (2008).
10. Reed E: ERCCl and clinical resistance to platinum-based therapy. Clin. Cancer Res. 11, 6100-6102 (2005). (Pubitemid 41262934)
11. Viguier J, Boige V, Miquel C et al.: ERCCl codon 118 polymorphism is a predictive factor for the tumour response to oxallplatin, 5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 11,6212-6217(2005). (Pubitemid 41262950)
12. Moreno V, Gemignani F, Land S et al.: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin. Cancer Res. 12, 2101-2108 (2006).
13. Stoehlmacher J, Ghaderi V, Iobal S et al.: A polymorphism of the XRCCl gene predicts for response to platinum based treatment in advanced colorectal cancer. Anticancer Res. 21 3075-3079(2001). (Pubitemid 33051178)
14. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61,8654-8658 (2001). (Pubitemid 34013872)
15. Etienne MC, Ilc K, Formento JL et al.: Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fuorouracil sensitivity. Br. J. Cancer 90, 526-534 (2004). (Pubitemid 38250655)
16. Adamo V, Franchina T, Adamo B et al.: Role of MTHFR polymorphism as predictive markers of acute toxicity during 5-fuorouracil based chemotherapy for colorectal cancer: preliminary data. J. Clin. Oncol. 26(Suppl. 20) (2008) (Abstract 15036).
17. Raida M, Schwabe W, Hausler P et al.: Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5́-splice donor site of intron 14 in patients with severe 5-fuorouracil (5-FU)-related toxicity compared with controls. Clin. Cancer Res. 7, 2832-2839 (2001). (Pubitemid 32911393)
18. Lenz H-J, Park DJ, Zhang W et al.: A multivariate ana lysis of genetic markers for clinical response to 5-FU oxaliplatin chemotherapy in advanced colorectal cancer. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 513).
19. Balboa E, Duran G, Lamas MJ et al.: Pharmacogenetic ana lysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. Pharmacogenomics 6, 747-761 (2010).
20. Spitz MR, Wu X, Wang Y et al.: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61, 1354-1357 (2001). (Pubitemid 34292555)
21. Quintela-Fandino M, Hitt R, Medina PP et al.: DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J. Clin. Oncol. 1024(26), 4333-4339 (2006). (Pubitemid 46630792)
22. Gao W, Romkes M, Zhong S et al.: Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol. Rep. 24(1), 257-262 (2010).
23. De Ruyck K, Szaumkessel M, De Rudder I et al.: Polymorphisms in base-excision repair and nucleotide-excision repair genes in relation to lung cancer risk. Mutat. Res. 631(2), 101-110 (2007). (Pubitemid 46921499)
24. Ban N, Takahashi Y, Takayama T et al.: Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56(15), 3577-3582 (1996). (Pubitemid 26251655)
25. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA: Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19(2), 275-280 (1998). (Pubitemid 28375421)
26. Le Morvan V, Bellott R, Moisan F, Mathoulin-Pélissier S, Bonnet J, Robert J: Relationships between genetic polymorphisms and anticancer drug cytotoxicity vis-à-vis the NCI-60 panel. Pharmacogenomics 7(6), 843-852 (2006). (Pubitemid 44446735)
27. Kweekel DM, Koopman M, Antonini NF et al.: GST P1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br. J. Cancer 99(8), 1316-1321 (2008).
28. Zarate R, Rodríguez J, Bandres E et al.: Oxaliplatin, irinotecan and capecitabine as frst-line therapy in metastatic colorectal cancer (mCRC): a dose-fnding study and pharmacogenomic ana lysis. Br. J. Cancer 102(6), 987-994 (2010).
29. McLeod HL, Sargent DJ, Marsh S et al.: Pharmacogenetic ana lysis of systemic toxicity and response after 5-fuorouracil (5FU), CPT-11, 5FU oxaliplatin (oxal), or CPT-11, oxal therapy for advanced colorectal cancer (CRC): results from an intergroup trial. Proc. Am. Soc. Clin. Oncol. 22, 253 (2003) (Abstract 1013).
30. Henderson CJ, McLaren AW, Moffat GJ, Bacon EJ, Wolf CR: Pi-class glutathione S-transferase: regulation and function. Chem. Biol . Interact. 111-112, 69-82 (1998). (Pubitemid 28271935)
31. Ruzzo A, Graziano F, Loupakis F et al.: Pharmacogenetic profling in patients with advanced colorectal cancer treated with frst-line-4 chemotherapy. J. Clin. Oncol. 25(10), 1247-1254 (2007). (Pubitemid 46640571)
32. 105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 12, 3050-3056 (2006). (Pubitemid 43837350)
33. Gamelin E, Gamelin L, Bossi L, Quasthoff S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin. Oncol. 29, 21-33 (2002) (Pubitemid 35191038)
34. Ishida S, Lee J, Thiele DJ, Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl Acad. Sci. USA 99, 14298-14302 (2002). (Pubitemid 35257666)
35. Martinez-Balibrea A, Abad A, Aranda E et al.; on behalf of the Spanish Group for the Treatment of Digestive Tumours (TTD Group) et al.: Pharmacogenetic approach for capecitabine or 5-fuorouracil selection to be combined with oxaliplatin as frst-line chemotherapy in advanced colorectal cancer. Eur. J. Cancer 44, 1229-1237 (2008).
36. Amado RG, Wolf M, Peeters M et al.: Wild-type Kras is required for panitumumab effcacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26(10), 1626-1634 (2008).
37. Maemondo M,Inoue A, Kobayashi K et al.: Geftinib or chemotherapy for no-small cell lung cáncer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).